Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetamide SCHEMBL28553648 | 0.93 | LMNA (0.47) | LMNAALOX15BLMPMP22TDP1 | |
| Trifluoroacetamide SCHEMBL28534339 | 0.90 | FFAR3 (0.47) | LMNAALOX15BLMPMP22TDP1 | |
| Trifluoroacetamide SCHEMBL27798795 | 0.90 | FFAR3 (0.47) | LMNAALOX15BLMPMP22TDP1 | |
| Trifluoroacetamide SCHEMBL27598858 | 0.89 | — | — | |
| Trifluoroacetamide SCHEMBL7739632 | 0.89 | — | — | |
| Trifluoroacetamide SCHEMBL142 | 0.89 | — | — | |
| Trifluoroacetamide SCHEMBL27678123 | 0.89 | LMNA (0.42) | LMNAALOX15BLMPMP22TDP1 | |
| Trifluoroacetamide SCHEMBL27887692 | 0.86 | — | — | |
| Trifluoroacetamide SCHEMBL6982843 | 0.85 | — | — | |
| Trifluoroacetamide SCHEMBL15993978 | 0.85 | LMNA (0.50) | LMNAALOX15BLMPMP22TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| EP-2987864-B1 | METHOD FOR DETECTING AN ANALYTE | STRATOS GENOMICS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180087103-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION AND RELATED METHODS | Roche Sequencing Solutions, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-9920386-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9771614-B2 | High throughput nucleic acid sequencing by expansion and related methods | STRATOS GENOMICS INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170037456-A1 | MULTIPLEXED IDENTIFICATION OF NUCLEIC ACID SEQUENCES | Roche Sequencing Solutions, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20110251079-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7939259-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-101910410-A | By carrying out high throughput nucleic acid sequencing at interval | STRATOS GENOMICS INC | 2010-12-08 | — | — | CN | disclosed |
| US-20100297644-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING | STRATOS GENOMICS INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2215259-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING | Stratos Genomics Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2171088-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009055617-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING | STRATOS GENOMICS INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2009-02-05 | — | — | US | disclosed |
| WO-2008157696-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | LMNA 233/4885ALOX15 4362/4885BLM 387/4885 |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | LMNA 233/4885ALOX15 4362/4885BLM 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.